

Lesotho

Support for Vaccine: Rotavirus This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Lesotho						
2. Vaccine grant number:	17-LSO-08b-Y, 17-LSO-13b-X, 18-LSO-13b-X, 1922-LSO-13b-X						
3. Date of Decision Letter:	30 September 2019						
4. Date of the Partnership Framework Agreement:	30 November 2012						
5. Programme title:	New Vaccine Support (NVS), Rotavirus, Routine						
6. Vaccine type:	Rotavirus						
7. Requested product presentation and formulation of vaccine:	RV1, 1 dose/plastic tube, liq						
8. Programme Duration:¹	2017-2022						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2017-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	332,566	82,000	123,000	121,000	-	-	658,566
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2017	17-LSO-08b-Y					100,000
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2017-2019						2020
Number of vaccine doses							34,400
Annual Amounts (US\$)	332,566						82,000

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																														
14. Self-procurement:	Not applicable																														
15. Co-financing obligations:	<p>According to the co-financing policy, the Country falls within the group: Preparatory transition phase</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2020</th> <th>2021</th> <th>2022</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>4,500</td> <td>7,500</td> <td>9,000</td> </tr> <tr> <td>Number of AD syringes</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of safety boxes</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>9,253</td> <td>16,280</td> <td>18,725</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>9,500</td> <td>17,000</td> <td>19,500</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2020	2021	2022	Number of vaccine doses	4,500	7,500	9,000	Number of AD syringes	-	-	-	Number of re-constitution syringes	-	-	-	Number of safety boxes	-	-	-	Value of vaccine doses (US\$)	9,253	16,280	18,725	Total co-financing payments (US\$) (including freight)	9,500	17,000	19,500
Type of supplies to be purchased with Country funds in each year	2020	2021	2022																												
Number of vaccine doses	4,500	7,500	9,000																												
Number of AD syringes	-	-	-																												
Number of re-constitution syringes	-	-	-																												
Number of safety boxes	-	-	-																												
Value of vaccine doses (US\$)	9,253	16,280	18,725																												
Total co-financing payments (US\$) (including freight)	9,500	17,000	19,500																												
16. Operational support for campaigns:	Not applicable																														
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> <p>31 March 2020</p> <p>15 May 2020</p> </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2020</p> <p>15 May 2020</p>	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																						
	Due dates																														
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2020</p> <p>15 May 2020</p>																														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																														
18. Financial clarifications:	Not applicable																														

19. Other conditions:

Not applicable

Signed by,
On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30 September 2019